Satellos Bioscience Inc · TSX:MSCL

Satellos Bioscience — CureDuchenne FUTURES National Conference 2025

11 slides from Satellos Bioscience's conference presentation, May 24, 2025

  1. Slide 1: CureDuchenne FUTURES National Conference

    © 2025 Satellos Bioscience CureDuchenne FUTURES National Conference Presenter: Frank Gleeson, Co-founder & CEO May 24, 2025 R E G E N E R AT I N G M U S C L E F R O M W I T H I N TM

  2. Slide 2: Legal Disclaimers

    © 2025 Satellos Bioscience Legal Disclaimers Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any The information contained herein is subject to change without statements that express or involve discussions with respect to predictions, expect

  3. Slide 3: Did you know?

    © 2025 Satellos Bioscience Did you know? In Duchenne, muscles are damaged faster than the body can repair and regenerate them as intended.

  4. Slide 4: Grounded in science. Inspired by need.

    © 2025 Satellos Bioscience About Satellos A New Way to Think About Treatment Grounded in science. ▪ We’re focused on helping muscle heal itself Inspired by need. How Our Approach Is Different Our mission is to restore muscle in Duchenne ▪ It is designed to improve muscle strength muscular dystrophy

  5. Slide 5: What We're Working On

    © 2025 Satellos Bioscience What We’re Working On SAT-3247 Designed to Inhibit AAK1 and At Satellos, we’re developing Replace a Missing Signal in Duchenne SAT-3247, a daily pill intended to One Progenitor to Generate One Stem Cell to restore repair and regeneration. Muscle Cells for Repair Maintain P

  6. Slide 6: Phase 1 Study Overview

    © 2025 Satellos Bioscience Phase 1 Study Overview Phase 1a Summary Phase 1b Study Design We tested SAT-3247 in 72 healthy ▪ Open-label study: people — from low to higher doses. ▪ Up to 10 patients over 18 years of age Reported at MDA in March 2025. ▪ Genetically confirmed with DMD ▪ Dosing: ▪ 60/mg

  7. Slide 7: SAT-3247 Displayed Encouraging Results in Phase 1b Study

    © 2025 Satellos Bioscience SAT-3247 Displayed Encouraging Results in Phase 1b Study Overview ▪ Open-label study ▪ Partnered with MDA Australia for recruitment ▪ 5 patients enrolled ▪ 5 patients completed ▪ Age range 20 - 27 ▪ All patients remained on daily steroids ▪ We are grateful to the patients

  8. Slide 8: SAT-3247 Displayed Encouraging Results in Phase 1b Study

    © 2025 Satellos Bioscience SAT-3247 Displayed Encouraging Results in Phase 1b Study Overview Data highlights ▪ Open-label study Safe and well tolerated ▪ Partnered with MDA Australia for recruitment SAT-3247 met desired PK ▪ 5 patients enrolled profile regardless of ▪ 5 patients completed concomitan

  9. Slide 9: SAT-3247 Displayed Encouraging Results in Phase 1b Study

    © 2025 Satellos Bioscience SAT-3247 Displayed Encouraging Results in Phase 1b Study Overview Data highlights Next steps in Ph 1 ▪ Open-label study ▪ 11-month follow-up study has Safe and well tolerated received ethics approval (AUS) ▪ Partnered with MDA Australia for recruitment o Up to 10 DMD adult

  10. Slide 10: SAT-3247 Phase 2 Proposed Study Design

    © 2025 Satellos Bioscience SAT-3247 Phase 2 Proposed Study Design Current Status Design ▪ Global, randomized, placebo-controlled, ▪ Finalizing standard preclinical studies required two-dose comparison to initiate Ph 2 treatment in children ▪ 3 months of treatment in pediatric DMD ▪ Multiple clinical

  11. Slide 11: © 2025 Satellos Bioscience

    © 2025 Satellos Bioscience 11

Satellos Bioscience — CureDuchenne FUTURES National Conference 2025 on 6ix